AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03801031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution intervention used to validate the effects of the lidocaine solution usage.
Trial: NCT00560573
Drug: CP-751,871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
Trial: NCT00726882
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment in prior ABT-333 studies.
Trial: NCT00347776
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral antibiotic
Trial: NCT00347776
Drug: topical tetracycline
RxNorm normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01788969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent + training vs Placebo + training
Trial: NCT03615040
Drug: MSTT1041A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSTT1041A (RO7187807; formerly made by Amgen \[AMG\] and referred to as AMG 282) is a novel biopharmaceutical that blocks signaling of interleukin (IL)-33, an inflammatory cytokine of the IL-1 family and member of the newly discovered alarmin class of molecules. IL-33 is released from airway epithelial cells in response to allergens, irritants, and infection. IL-33 release can trigger acute exacerbations in both asthma and COPD. MSTT1041A has the ability to block inflammation,prevent exacerbations, and improve lung function and quality of life.~Anti-ST2 is presented as sterile, clear, and colourless to slightly yellow liquid. Each sterile vial is filled with a 1 mL deliverable volume of 70 mg/mL. It is formulated with 15 mM sodium acetate, 9.0% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 5.2.
Trial: NCT03615040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Anti-ST2 (MSTT1041A) is formulated with 10 mM sodium acetate, 9.0% (w/v) sucrose, 0.004% (w/v) polysorbate 20, pH 5.2, and is supplied in an identical vial configuration.
Trial: NCT01776307
Drug: BBI608
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBI608 is administered at 500 mg po bid continuously.
Trial: NCT01776307
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.
Trial: NCT00866697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
Trial: NCT02577601
Drug: Levonorgestrel (LNG)/Ethinyl estradiol birth control pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00007813
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04004871
Drug: Nab-paclitaxel, Cisplatin and Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive Nab-paclitaxel (200mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before concurrent chemoradiotherapy.
Trial: NCT00573144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 72 hours of saline solution (packaged to match active comparator)
Trial: NCT02546700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered subcutaneously once in every 4 weeks.
Trial: NCT03735680
Drug: ONM-100
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A polymer micelle covalently conjugated to indocyanine green.
Trial: NCT01639729
Drug: Treatment A: Sufentanil IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
Trial: NCT01422876
Drug: high dose FDC placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT01639729
Drug: Treatment B: Sufentanil NanoTab Sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Sufentanil NanoTab 15 mcg given sublingually (SL)
Trial: NCT01639729
Drug: Treatment C: Sufentanil NanoTab Buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
Trial: NCT01639729
Drug: Treatment D: Sufentanil NanoTab Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Sufentanil NanoTab 15 mcg swallowed (PO)
Trial: NCT01422876
Drug: low dose FDC placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT02641340
Drug: Fentanyl Sublingual Spray
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)
Trial: NCT01422876
Drug: high dose BI 10773 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT02641340
Drug: Fentanyl Citrate IV
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl Citrate 50 mcg, delivered intravenously
Trial: NCT01422876
Drug: BI 10773 low dose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT01422876
Drug: low dose BI 10773 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT01015638
Drug: Clindamycin and BPO 5% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
Trial: NCT01015638
Drug: Clindamycin phosphate and benzoyl peroxide 2.5% gel.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel
Trial: NCT01905631
Drug: Aurstat Anti-Itch Hydrogel (Aurstat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
Trial: NCT04220073
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00299546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injections
Trial: NCT03404024
Drug: Stage 2-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 0: 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl)
Trial: NCT00863213
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.
Trial: NCT01090323
Drug: ICL670
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.
Trial: NCT03514446
Drug: Antibiotic therapy duration for 7 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy for seven days
Trial: NCT01766505
Drug: Candemore tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.~dosage is depends on the sitting blood pressure.
Trial: NCT03842202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive once weekly injections of semaglutide matched placebo.
Trial: NCT00460421
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose etoposide, Cyclophosphamide
Trial: NCT00711477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03043105
Drug: Thalidomide, cyclophosphamide and prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Thalidomide: 100mg QN for 1 year; And maintained with 100mg QN for the second year;~* Cyclophosphamide: 300mg/m2 on Day 1, 8, 15, 22 every month for 1 year;~* Prednisone: 1mg/kg on Day 1-2, 8-9, 15-16, 22-23 every month for 1 year.
Trial: NCT00743106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion(0.9% Nacl) beginning during surgery and lasting for up 24 hours post surgery
Trial: NCT02194374
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FCR Regimen : 250 mg/m2 by vein on Days -5, -4, and -3.
Trial: NCT00799214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
Trial: NCT03386838
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m² per day for 4 days, every 3 weeks (Up to 6 cycles)
Trial: NCT00829192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous implant administered every 60 days
Trial: NCT01016366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
Trial: NCT03018756
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mcg fentanyl citrate will be inhaled via nebulizer.
Trial: NCT03018756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution will be inhaled via nebulizer
Trial: NCT01640834
Drug: LY2409021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01640834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01765218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo identical in appearance to the active agent (topiramate)
Trial: NCT01035411
Drug: AZD9668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 30 mg batch DLE494
Trial: NCT01035411
Drug: AZD9668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 30 mg batch DLF497
Trial: NCT01035411
Drug: AZD9668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 30 mg tablet variant 1
Trial: NCT00575484
Drug: Normal saline, then oral placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.
Trial: NCT01114126
Drug: Neu-P11 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different dosages
Trial: NCT04100902
Drug: ODACTRA 12 SQ-HDM Sublingual Tablet
RxNorm normalized name: ODACTRA 12 SQ-HDM Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
Trial: NCT04100902
Drug: Placebo sublingual tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
Trial: NCT04556383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT00615927
Drug: Imatinib Mesylate & Hydroxyurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib administered orally on daily. Imatinib is local irritant \& must be taken in sitting position; mini of 2hrs should be allowed between last drug intake \& going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/\> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues.~Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 \& continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts.
Trial: NCT02269800
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tid, 7 days
Trial: NCT04128059
Drug: BVRS-GamVac-Combi
RxNorm normalized name: NexGard Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration
Trial: NCT02762370
Drug: FX006 32 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5 mL IA injection
Trial: NCT02762370
Drug: TCA IR 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 1 mL IA injection
Trial: NCT00029770
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00029770
Drug: Non-Steroidal anti-inflammatory drugs (NSAIDS)
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00246740
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
Trial: NCT00528697
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.
Trial: NCT00528697
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will take a tablet once daily for 8 weeks
Trial: NCT00101452
Drug: S-adenosyl-l-methionine
RxNorm normalized name: S-Adenosyl-L-Methionine (Sam-E)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg per day with possibility of increasing to 3200 mg per day at 6 weeks
Trial: NCT00101452
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules look like escitalopram capsules and SAMe capsules
Trial: NCT01994889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in soft gel capsules administered once a day for 30 months
Trial: NCT03297710
Drug: Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00964210
Drug: Licensed quadrivalent HPV vaccine, Gardasil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.
Trial: NCT02185924
Drug: N/S 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01779258
Drug: glycerol, paraffin (liquid and white soft)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 application in the morning and in the evening
Trial: NCT01779258
Drug: Locatop@
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the Run-In period:~1 application in the morning and in the evening during a maximum of 21 days
Trial: NCT01779258
Drug: Locapred@
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the 3 months study treatment:~1 application in the evening in case of flare
Trial: NCT04520451
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet or capsule
Trial: NCT00054340
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00054340
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02975557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
Trial: NCT03423199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Trial: NCT00600977
Drug: Doxorubicine pegylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 MG/M² J1 2 courses
Trial: NCT03050229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily before or after breakfast
Trial: NCT00849095
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bid inhaled placebo
Trial: NCT02408159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03158285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo as SC injection.
Trial: NCT02200640
Drug: High dose of Micardis®, once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02200640
Drug: Low dose of Micardis®, once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02200640
Drug: Low dose of COZAAR®, once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02200640
Drug: High dose of COZAAR®, once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02200640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03456076
Drug: Alectnib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive alectinib 600 mg orally BID until completion of treatment period (24 months) or recurrence of disease , unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
Trial: NCT03111186
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400 mg up to six times daily as needed for pain
Trial: NCT03111186
Drug: Acetaminophen 650 mg
RxNorm normalized name: acetaminophen 650 MG
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg up to four times daily as needed for pain
Trial: NCT04270370
Drug: LY3478045
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04270370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03510741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to TAU
Trial: NCT03510741
Drug: Sodium Benzoate Plus N-Acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
Trial: NCT01106716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV Infusion
Trial: NCT02879006
Drug: Chinese Herbal Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, 26 month course, starting 2 months pre-OIT
Trial: NCT02879006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT
Trial: NCT00276458
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
Trial: NCT04000958
Drug: Regular treament
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
Trial: NCT02151552
Drug: Endotoxin (E. coli O:113, Reference Endotoxin)
RxNorm normalized name: E.COLI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
Trial: NCT02151552
Drug: [18F](+/-)NOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mCi of \[18F\](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
Trial: NCT02879006
Drug: Multi OIT
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 months of multi OIT (maintenance dose of 1gm each food allergen)
Trial: NCT00186875
Drug: methotrexate, teniposide, PEG-asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description section for details of treatment interventions.
Trial: NCT00186875
Drug: mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description section for details of treatment interventions.
Trial: NCT00186875
Drug: L-asparaginase, erwinia asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description section for details of treatment interventions.